News for Immutep Limited (IMM.AX)

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol ap

**media[575885]**

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial in its final stage of clinical study.

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; IMMP) (”œImmutep” or ”œthe Company”), a late-stage immunotherapy comp

**media[571871]**

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against the other long term ASX ...

**media[528993]**

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best ASX...

Immutep Limited (IMMP) is a promising biotech stock with a strong pipeline and solid financial foundation, making it a buy despite risks.

According to a report by Vanguard published on January 24, Australia's economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024.

**media[521487]**

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of ap

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has seen no adverse effects.

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therap

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-t

**media[490451]**

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside with phase 3 and 2b trials ahead.

**media[466242]**

**media[466206]**